Howard M. Lederman, MD

Dr. Streiff's major clinical interest involves the prevention and treatment of venous thromboembolism. He has written several comprehensive reviews on vena caval filters and the management of venous thromboembolism in cancer patients. He chairs the Venous Thromboembolism Guideline Committee for the National Comprehensive Cancer Center Network and has served on international consensus panels to develop standardized guidelines for the use of vena caval filters in the management of venous thromboembolism. As a member of a Johns Hopkins Evidence-Based Practice Center panel, he participated in the development of evidence reports on the management of venous thromboembolism. His research on patients with malignant gliomas identified ABO blood group as a novel risk factor for VTE in this population. A multicenter clinical trial is now nearing completion to confirm these results and identify plasma markers of increased risk for venous thromboembolism in glioma patients. As Medical Director of the Anticoagulation Management Service and Outpatient Clinics, he and his colleagues from the Department of Pharmacy have been actively involved in developing policies and procedures for standardizing anticoagulation management and guidelines for VTE prevention at the Johns Hopkins Medical Institutions. As the consulting Hematologist for the Johns Hopkins Comprehensive Hemophilia Treatment Center, he is actively involved in the diagnosis and treatment of patients with hemophilia, von Willebrand disease and other hemostatic disorders.

Dr. James Eshleman is a professor of pathology and oncology at the Johns Hopkins University School of Medicine and a member of its Kimmel Cancer Center. His areas of clinical expertise includes molecular diagnosis. Dr. Eshleman serves as the associate director of the Molecular Diagnostics Laboratory at the Johns Hopkins School of Medicine. Dr. Eshleman earned his M.D. and Ph.D. from the University of Pennsylvania School of Medicine. He completed a residency in clinical pathology and a fellowship in blood banking and transfusion medicine at the Hospital of the University of Pennsylvania. His research interest is genetically killing pancreatic cancer using CRISPR-Cas9 by targeting somatic mutations, and developing new molecular pathology tools.

Dr. Peter Bela Illei is an associate professor of pathology in the Division of Cytopathology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include pulmonary pathology, transplant pathology, cytopathology and lung cancer biomarkers.Dr. Illei earned his medical degree from University of Pécs School of Medicine. He completed his residency at New York University Medical Center in pathology and performed a fellowship in oncologic pathology and cytopathology at Memorial Sloan Kettering Cancer Center.Dr. Illei’s research interests include development of novel immunohistochemical and molecular markers for the diagnosis of solid tissue tumors, pathology of lung cancer and mesothelioma, as well as lung transplantation.